Paucinervin ACAS# 1243249-16-2 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1243249-16-2 | SDF | Download SDF |
PubChem ID | 52949770 | Appearance | Powder |
Formula | C24H26O7 | M.Wt | 426.46 |
Type of Compound | Xanthones | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2,7,9-trihydroxy-1-methoxy-3,8-bis(3-methylbut-2-enyl)benzo[b][1,4]benzodioxepin-6-one | ||
SMILES | CC(=CCC1=CC2=C(C(=C1O)OC)OC3=CC(=C(C(=C3C(=O)O2)O)CC=C(C)C)O)C | ||
Standard InChIKey | CZKGIKZOHGKQSQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H26O7/c1-12(2)6-8-14-10-18-22(23(29-5)20(14)26)30-17-11-16(25)15(9-7-13(3)4)21(27)19(17)24(28)31-18/h6-7,10-11,25-27H,8-9H2,1-5H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Paucinervin A has inhibitory effect against HeLa cell growth, with the IC50 value of 29.5 microM. |
Paucinervin A Dilution Calculator
Paucinervin A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3449 mL | 11.7244 mL | 23.4489 mL | 46.8977 mL | 58.6221 mL |
5 mM | 0.469 mL | 2.3449 mL | 4.6898 mL | 9.3795 mL | 11.7244 mL |
10 mM | 0.2345 mL | 1.1724 mL | 2.3449 mL | 4.6898 mL | 5.8622 mL |
50 mM | 0.0469 mL | 0.2345 mL | 0.469 mL | 0.938 mL | 1.1724 mL |
100 mM | 0.0234 mL | 0.1172 mL | 0.2345 mL | 0.469 mL | 0.5862 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- LGK-974
Catalog No.:BCC5103
CAS No.:1243244-14-5
- Wnt-C59
Catalog No.:BCC3965
CAS No.:1243243-89-1
- RN486
Catalog No.:BCC3921
CAS No.:1242156-23-5
- 12-Ursene-3,16,22-triol
Catalog No.:BCN6126
CAS No.:1242085-06-8
- Laxiracemosin H
Catalog No.:BCN6910
CAS No.:1241871-28-2
- 6-O-Vanilloylajugol
Catalog No.:BCN6125
CAS No.:124168-04-3
- (R)-DRF053 dihydrochloride
Catalog No.:BCC7726
CAS No.:1241675-76-2
- Alcesefoliside
Catalog No.:BCN2933
CAS No.:124151-38-8
- Scutebarbatine O
Catalog No.:BCN8377
CAS No.:960302-88-9
- 2-Hydroxytetracosanoic acid ethyl ester
Catalog No.:BCN1599
CAS No.:124111-47-3
- 1-Caffeoylquinic acid
Catalog No.:BCN5911
CAS No.:1241-87-8
- (-)-Hydroxydihydrobovolide
Catalog No.:BCN7890
CAS No.:124097-54-7
- Lenalidomide hydrochloride
Catalog No.:BCC1697
CAS No.:1243329-97-6
- 9-(1H-Benzotriazol-1-ylmethyl)-9H-carbazole
Catalog No.:BCC8792
CAS No.:124337-34-4
- MG 149
Catalog No.:BCC5149
CAS No.:1243583-85-8
- Cannabidiolic acid
Catalog No.:BCN6127
CAS No.:1244-58-2
- CGS 21680 HCl
Catalog No.:BCC4316
CAS No.:124431-80-7
- VU 0364739 hydrochloride
Catalog No.:BCC7875
CAS No.:1244640-48-9
- 16R-sitsirikine
Catalog No.:BCN3492
CAS No.:1245-00-7
- 2,2'-Bicinchoninic acid
Catalog No.:BCC8487
CAS No.:1245-13-2
- Retusin
Catalog No.:BCN7794
CAS No.:1245-15-4
- 16-Oxoalisol A
Catalog No.:BCN3460
CAS No.:124515-98-6
- PI4KIII beta inhibitor 3
Catalog No.:BCC1310
CAS No.:1245319-54-3
- Glucocorticoid receptor agonist
Catalog No.:BCC1596
CAS No.:1245526-82-2
Identification and evaluation of apoptotic compounds from Garcinia paucinervis.[Pubmed:20594858]
Bioorg Med Chem. 2010 Jul 15;18(14):4957-64.
Four new compounds, paucinervins A-D (1-4), and 15 known ones were isolated from the leaves of Garcinia paucinervis. The structures of the new compounds were elucidated by spectroscopic evidences. All of the 19 compounds were evaluated for their apoptosis-inducing effects using HeLa-C3 cells which have been genetically engineered to possess a fluorescent biosensor capable of detecting caspase-3 activation. Eight of them were found to activate caspase-3 in HeLa-C3 cells within 72 h at the concentration of 25 microM. Moreover, the values of IC50 were measured for all four new compounds on HeLa cells using the MTT assay. Among them, compound 2 (paucinervin B) had the lowest IC50 value of 9.5 microM, while the other three new compounds had much higher IC50 values of 29.5, 52.5, and 95.6 microM, respectively. This result shows that paucinervin B has the strongest inhibitory effect against HeLa cell growth among these four newly identified paucinervins and it may have the potential to be developed into a new anticancer candidate.